Microbio is pleased to announce it has signed a new distribution agreement with YouDoBio, a molecular diagnostics provider based in Denmark. Under the agreement, YouDoBio will become the exclusive distributor of Microbio’s InfectID™-BSI molecular assay in Denmark.
YouDoBio brings deep expertise in molecular diagnostics, a strong presence in Danish clinical labs and healthcare institutions, and a commitment to rapid and accurate infectious disease diagnostics. This partnership will enable Danish clinicians and laboratories to access InfectID™-BSI for faster identification of bloodstream infections and improved treatment decisions.
“We’re excited to partner with YouDoBio to bring InfectID™-BSI into Denmark,” said Paul Rainey, Distributor Manager at Microbio. “Having a local partner who understands the regulatory landscape, laboratory network and clinical needs in Denmark means this technology can make a real impact — helping clinicians detect bloodstream infections faster, initiate appropriate therapy sooner, and improve patient outcomes.”
“Denmark continues to lead in implementing cutting-edge healthcare innovations. InfectID™–BSI provides a novel solution for rapid identification of bloodstream infections, enabling timely treatment of sepsis and advancing antibiotic stewardship practices in modern healthcare systems” said Peter Roberts, Managing Director at YouDoBio.
InfectID™-BSI is a rapid molecular diagnostic test that identifies 26 pathogens responsible for >94% of bloodstream infections resulting in sepsis. Leveraging DNA melt curve analysis, InfectID™-BSI detects pathogens directly from blood samples without the need for culture, delivering results in just three hours. This CE-marked assay empowers clinicians to begin targeted treatment sooner, improving outcomes and supporting antimicrobial stewardship.
This agreement extends Microbio’s global reach and is a key milestone in its European expansion strategy.